False resistance after artemether-lumefantrine treatment in a falciparum malaria patient in Turkey: A case report.

Autor:	Koru O; Gulhane Training and Research Hospital, Department of Medical Microbiology, Etlik, Ankara, Turkey., Yazici E; World Health Organization, 20 Avenue Appia, 1211, Geneva 27, Switzerland., Rasmussen C; Gulhane Training and Research Hospital, Department of Infectious Diseases, Etlik, Ankara, Turkey., Ringwald P; Gulhane Training and Research Hospital, Department of Infectious Diseases, Etlik, Ankara, Turkey., Artuk C; World Health Organization, 20 Avenue Appia, 1211, Geneva 27, Switzerland., Bedir O; Gulhane Training and Research Hospital, Department of Medical Microbiology, Etlik, Ankara, Turkey.
Jazyk:	angličtina
Zdroj:	IDCases [IDCases] 2019 Oct 10; Vol. 18, pp. e00607. Date of Electronic Publication: 2019 Oct 10 (Print Publication: 2019).
DOI:	10.1016/j.idcr.2019.e00607
Abstrakt:	Introduction: Artemisinin-based combination therapy (ACT) is recommended by the World Health Organization as first-line treatment of uncomplicated Plasmodium falciparum malaria. ACT treatments failures among travellers returning from Africa to non-endemic countries are considered to be caused by resistance. Case Presentation: We report on a case of artemether-lumefantrine treatment failure in a Turkish traveller with uncomplicated P. falciparum malaria returning from Bamako, Mali. Conclusions: Information on returning travellers, includes ensuring that the patients receive supervised treatment with the recommended dose of a quality controlled medicine, routine follow-up of all cases, assessment of adequate absorption of the drug, and/or testing the prevalence of molecular markers of drug resistance if validated, can be an important source of an early warning system for emerging resistance. Competing Interests: None of the authors report any conflicts of interest. (© 2019 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu